Clinical Trial Detail

NCT ID NCT02481050
Title Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Eisai Inc.
Indications

Her2-receptor negative breast cancer

Therapies

Eribulin

Age Groups: adult

Additional content available in CKB BOOST